「mr」の検索結果
55件：6～10件目を表示
-
ral Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that the orphan drug designation to the in...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240708.pdf -
oftware for Dry-eye Analysis Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of software for...
https://www.senju.co.jp/system/files/content_news/2024-09/ENG_20240906_0.pdf -
ral Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that the orphan drug designation to the in...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240708_0.pdf -
ral Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that it has started Phase III clinical tri...
https://www.senju.co.jp/system/files/content_news/2024-05/ENG_20240509.pdf -
ent with Brill International Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that it has entered into a LicensingAgreem...
https://www.senju.co.jp/system/files/content_news/2025-03/ENG_20250307_0.pdf